Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world? (PubMed, Haematologica) - Oct 9, 2026 - "At a median follow-up of 12.6 months, 1-year progression-free survival (PFS) and overall survival (OS) in OA were 91.5% and 98.6%, respectively. OS was inferior in OA compared with patients."
Journal • Real-world evidence • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology
|
|
Ajay Major; Alex Herrera; Alex Niu; Allison M Bock; Ayo Falade; Calvin Lee; Catherine Diefenbach; Dahlia Sano; Daniel Reef; Drew Gerber; Efrat Luttwak; Gordon Smilnak; Grace Baek; Harsh R Shah; Hua-Jay J Cherng; Jakub Svoboda; Joanna M Rhodes; John Sharp; John Vaughn; Kanithra Sekaran; Krithika Shanmugasundaram; Madiha Iqbal; Marisa Palmeri; Mengyang Di; Narendranath Epperla; Natalie Grover; Nicole Araujo; Pallawi Torka; Peirong Hao; Praveen Ramakrishnan Geethakumari; Priyanka Pophali; Reem Karmali; Ritwick Mynam; Swetha K Thiruvengadam; Tatyana Feldman; Timothy Voorhees; Urshila Durani; Vrutti Patel; Yasmin Karimi; Yizhe Xu
|